Lincotek, a worldwide additive manufacturing options supplier, has named Gianluca Fioravanti as World Normal Supervisor of its Medical Division. Fioravanti will report on to Group CEO Andrea Colombo, and can lead the event and execution of the corporate’s world development technique throughout all areas.
Fioravanti brings greater than 25 years of worldwide expertise within the medical sector, with a background spanning operations, engineering and normal administration. He holds a level in Electronics Engineering and an Govt MBA, and beforehand held senior roles at Pfizer, Baxter, Novartis, GSK Vaccines and Johnson & Johnson.
“Gianluca brings intensive expertise of extremely regulated and technologically superior environments, particularly within the orthopedic trade,” acknowledged Andrea Colombo, Group CEO of Lincotek. “His confirmed monitor report of managing complicated worldwide environments and driving transformation applications will likely be extremely vital as we work to optimize the service we offer to prospects.
“This may additional reinforce our function as a trusted accomplice in serving to them navigate more and more complicated challenges. We’re thrilled to have him on board.”
Fioravanti most just lately served as Senior Operations World Director at Jabil Healthcare, the place he oversaw a community of 12 manufacturing websites throughout Europe and the US and managed greater than 4,000 folks.
“It’s really an honor to hitch Lincotek at such an necessary second within the firm’s evolution,” stated Fioravanti. “I’m genuinely impressed by the dedication and experience of the groups throughout the Medical Division, who characterize a rare wealth of professionalism and keenness. Collectively, we intention to strengthen our world affect whereas accelerating innovation throughout the complete worth chain — from advancing our manufacturing applied sciences to delivering more and more subtle options for our OEM companions.
“I’m excited to collaborate with these distinctive groups to drive additional progress and create even better worth for our prospects within the years forward.”
Lincotek began the yr by acquiring FDA clearance for its pioneering SpineLinc anterior cervical implant system.
The corporate has additionally considerably expanded its manufacturing footprint over the past 18 months, practically doubling the dimensions of its high-tech Trento (Italy) primarily based headquarters.